human
immunodefici
viru
type
viru
know
klatt
et
al
antigen
structur
analyz
consider
detail
norrbi
wyatt
et
al
zollapazn
montero
et
al
hoxi
mani
studi
devot
envelop
glycoprotein
env
present
spike
embed
viral
membran
function
spike
consist
trimer
three
surfac
glycoprotein
noncoval
attach
three
transmembran
glycoprotein
addit
function
trimer
viral
membran
may
also
display
monom
singl
molecul
nonfunct
fragment
poignard
et
al
moor
et
al
crook
et
al
antigen
spike
studi
extens
numer
env
epitop
shown
induc
wide
rang
neutral
antibodi
infect
individu
zollapazn
javaherian
et
al
muster
et
al
zwick
et
al
poignard
et
al
gorni
et
al
dhillon
et
al
li
et
al
hioe
et
al
result
antigen
site
env
protein
consid
promis
candid
develop
prevent
hiv
vaccin
abl
provid
prophylact
immun
zwick
zwick
burton
willey
aasachapman
binley
stamatato
et
al
strategi
tri
develop
vaccin
studi
interact
human
mab
env
epitop
call
revers
vaccinolog
attempt
gener
vaccin
known
structur
neutral
antibodi
rather
follow
revers
common
approach
gener
protect
antibodi
immun
burton
crystallograph
studi
structur
env
epitop
recogn
neutral
mab
often
claim
data
help
ration
design
vaccin
immunogen
abl
elicit
antibodi
endow
neutral
capac
mab
use
defin
epitop
schief
et
al
saphir
et
al
karlssonhedestam
et
al
vaccin
develop
term
design
usual
mean
select
vaccin
candid
find
appropri
vaccin
formul
schedul
adjuv
rout
administr
strategi
ration
structurebas
design
discuss
circumscrib
sinc
refer
develop
optim
vaccin
immunogen
within
restrict
context
singl
mabantigen
pair
approach
assum
viral
antigen
modifi
bind
better
neutral
mab
acquir
immunogen
capac
elicit
neutral
polyclon
antibodi
van
regenmortel
argu
claim
revers
vaccinolog
base
misconcept
regard
natur
protein
epitop
immunolog
specif
assumpt
discontinu
epitop
defin
xray
crystallographi
act
effect
vaccin
immunogen
without
embed
multiepitop
protein
alway
induc
mani
differ
type
antibodi
belief
effect
vaccin
immunogen
predict
antigen
structur
viral
antigen
bound
neutral
mab
research
carri
last
two
decad
demonstr
revers
vaccinolog
abl
guid
design
hiv
vaccin
present
review
expand
earlier
analysi
limit
revers
vaccinolog
van
regenmortel
show
antibodi
polyspecif
explain
elucid
structur
viral
epitop
recogn
neutral
mab
littl
use
discov
immunogen
capabl
induc
protect
immun
respons
may
advis
therefor
shift
current
emphasi
hiv
vaccin
research
ration
design
approach
base
structur
analysi
env
epitop
empir
approach
investig
possibl
therapeut
benefit
may
result
administr
varieti
vaccin
immunogen
caputo
et
al
region
antigen
molecul
recogn
antibodi
molecul
call
epitop
region
antibodi
bind
epitop
call
paratop
region
identifi
solv
structur
antigenantibodi
complex
determin
amino
acid
residu
two
partner
make
contact
vast
major
protein
epitop
found
discontinu
atassi
smith
barlow
et
al
sundberg
mariuzza
consist
two
five
short
stretch
residu
distant
protein
sequenc
brought
togeth
fold
peptid
chain
epitop
character
discontinu
epitop
thali
et
al
moor
ho
van
cott
et
al
zwick
et
al
atom
group
form
discontinu
epitop
held
togeth
intern
chemic
bond
epitop
entiti
emerg
chain
act
scaffold
scaffold
perturb
instanc
chang
chain
conform
denatur
protein
epitop
ceas
exist
laver
et
al
van
regenmortel
discontinu
epitop
extract
isol
activ
form
protein
antigen
possess
bind
activ
within
context
protein
structur
embed
fig
spite
claim
contrari
possibl
predict
exact
structur
discontinu
epitop
nucleotid
amino
acid
sequenc
hopp
van
regenmortel
pellequ
ponomarenko
van
regenmortel
second
type
protein
epitop
known
continu
epitop
defin
short
peptid
fragment
protein
usual
five
eight
residu
long
abl
crossreact
antibodi
rais
protein
linear
peptid
given
statu
continu
epitop
protein
impress
creat
epitop
actual
exist
discret
bind
immunogen
site
nativ
protein
case
howev
residu
continu
epitop
locat
surfac
nativ
protein
usual
part
complex
discontinu
epitop
fig
although
epitop
databas
list
thousand
continu
epitop
presum
exist
individu
protein
greenbaum
et
al
zhang
et
al
linear
peptid
actual
poor
mimic
larger
antigen
structur
present
nativ
protein
mostli
crossreact
weakli
antiprotein
antibodi
van
regenmortel
structur
continu
epitop
bound
antipeptid
antibodi
compar
structur
correspond
region
cognat
nativ
protein
two
structur
usual
found
differ
consider
result
antibodi
rais
peptid
unabl
bind
parent
protein
bump
clash
prevent
antibodi
bind
chen
et
al
continu
epitop
alway
illdefin
fuzzi
boundari
defin
bind
activ
rather
show
residu
peptid
interact
antiprotein
antibodi
van
regenmortel
attempt
sometim
made
assess
boundari
continu
epitop
measur
bind
activ
peptid
decreas
size
give
statu
epitop
smallest
peptid
retain
detect
activ
howev
result
analys
depend
immunoassay
use
peptid
conform
usual
differ
differ
type
assay
muller
et
al
assay
tripeptid
shown
possess
signific
bind
activ
trifilieff
et
al
contribut
individu
residu
epitop
activ
also
evalu
measur
bind
capac
set
peptid
analog
present
singl
residu
replac
done
certain
residu
found
essenti
bind
other
call
replac
residu
replac
amino
acid
without
impair
antigen
reactiv
getzoff
et
al
geysen
et
al
residu
substitut
found
affect
epitop
activ
could
mean
residu
contact
paratop
substitut
induc
conform
chang
affect
reactiv
peptid
suggest
continu
epitop
genuin
epitop
nativ
protein
correspond
unfold
region
denatur
protein
recogn
antibodi
direct
denatur
molecul
laver
et
al
inde
never
exclud
antiprotein
antiserum
use
detect
continu
epitop
contain
antibodi
specif
denatur
protein
molecul
protein
molecul
use
immun
becam
denatur
inject
anim
jemmerson
reciproc
situat
antibodi
rais
peptid
allow
react
cognat
protein
also
exclud
antibodi
recogn
denatur
protein
molecul
present
immunoassay
format
use
spangler
accept
instanc
earlier
claim
immun
peptid
alway
elicit
high
level
antibodi
crossreact
nativ
cognat
protein
lerner
aros
realiz
time
protein
use
solidphas
immunoassay
becam
denatur
adsorpt
plastic
van
regenmortel
darst
et
al
classif
epitop
either
continu
discontinu
may
give
impress
fundament
unit
antigen
recognit
amino
acid
residu
although
epitopeparatop
interact
involv
atom
residu
may
side
chain
main
chain
atom
also
appreci
crystallograph
often
use
differ
criteria
identifi
contact
residu
involv
interfac
getzoff
et
al
instanc
contact
residu
epitop
defin
atom
less
nm
away
atom
antibodi
hafenstein
et
al
distanc
threshold
use
identifi
differ
type
contact
instanc
nm
hydrogen
bond
salt
bridg
nm
van
der
waal
interact
nm
cation
interact
chen
et
al
use
differ
threshold
may
lead
differ
residu
attribut
bind
interfac
anoth
type
linear
peptid
epitop
recogn
given
label
mimotop
geysen
et
al
mimotop
detect
peptid
combinatori
peptid
librari
obtain
chemic
synthesi
phage
display
test
abil
bind
antiprotein
mab
recogn
either
continu
discontinu
epitop
irv
et
al
mab
direct
discontinu
epitop
may
bind
peptid
show
littl
sequenc
similar
antigen
use
elicit
antiprotein
antibodi
antigen
crossreact
occur
absenc
sequenc
similar
may
aris
overrid
attract
hydrophil
hydrophob
group
occur
pattern
hydropath
complementar
conserv
dissimilar
peptid
sequenc
hanin
et
al
van
regenmortel
phenomenon
respons
bind
complementari
peptid
specifi
sens
antisens
strand
rna
molecul
respect
codon
alway
code
amino
acid
opposit
hydropath
blalock
tropsha
et
al
mab
use
detect
mimotop
recogn
continu
epitop
protein
sometim
extens
sequenc
ident
mimotop
continu
epitop
case
two
neutral
mab
recogn
sequenc
present
surfac
glycoprotein
murin
coronaviru
sever
mimotop
found
two
mab
present
littl
similar
heavi
chain
complementar
determin
region
cdr
indic
two
paratop
recogn
similar
sequenc
differ
yu
et
al
also
often
found
mab
harbour
unrel
paratop
abl
recogn
similar
discontinu
epitop
malbi
et
al
lescar
et
al
van
regenmortel
suggest
may
difficult
control
type
antibodi
obtain
similar
epitop
use
immunogen
limit
number
mimotop
may
also
abl
induc
antibodi
crossreact
protein
delmastro
et
al
puntoriero
et
al
larrald
et
al
show
modest
capac
neutral
viral
infect
schelleken
et
al
steward
et
al
antigen
immunogen
activ
mimotop
often
depend
conform
instanc
mimotop
display
phage
may
better
mimic
conform
viral
epitop
use
free
peptid
conjug
carrier
protein
irv
et
al
zwick
et
al
dorgham
et
al
mimotop
display
phage
protein
may
also
better
elicitor
antibodi
crossreact
viru
neutral
infect
yu
et
al
although
sever
mimotop
epitop
isol
combinatori
peptid
librari
zwick
et
al
dorgham
et
al
keller
et
al
boot
et
al
scala
et
al
none
abl
use
immunogen
elicit
adequ
level
neutral
protect
antibodi
mani
peptid
given
label
mimotop
cross
react
antiprotein
mab
necessarili
bind
residu
known
antiprotein
paratop
sinc
may
interact
neighbour
residu
part
differ
paratop
recogn
mimotop
result
mani
socal
mimotop
realli
mimic
epitop
recogn
mab
simpli
react
polyspecif
immunoglobulin
ig
molecul
alway
possess
numer
potenti
bind
site
differ
epitop
commonli
use
procedur
assess
mimotop
recogn
test
whether
abl
inhibit
bind
mab
homolog
antigen
mimotop
found
compet
antigen
bind
mab
usual
taken
suffici
evid
mimic
epitop
recogn
mab
irv
et
al
zwick
et
al
criterion
establish
mimicri
actual
question
sinc
bind
inhibit
could
simpli
due
fact
steric
hindranc
prevent
mimotop
bind
neighbour
paratop
ig
bind
pocket
mab
antibodi
recogn
two
unrel
epitop
separ
nonoverlap
paratop
would
cours
make
littl
sens
say
two
epitop
antigen
mimic
mimotop
present
sequenc
similar
portion
epitop
taken
evid
mimotop
bind
put
paratop
mab
howev
equal
plausibl
mimotop
bind
specif
site
consist
neighbour
set
residu
furthermor
mimotop
abl
elicit
antibodi
recogn
epitop
believ
mimick
taken
confirm
evid
mimotop
exactli
mimick
epitop
antigen
mimicri
display
mimotop
howev
impli
peptid
precis
structur
mimic
make
ident
contact
paratop
made
epitop
elicit
antibodi
sinc
modest
similar
two
antigen
may
suffici
give
rise
crossreact
involv
overlap
differ
paratop
concept
immunogen
mimicri
even
difficult
defin
structur
term
antigen
mimicri
sinc
involv
undefin
function
activ
immun
host
well
unknown
characterist
immunogen
elicit
appear
crossreact
antibodi
irv
et
al
concept
specif
immunolog
difficult
defin
cohn
langman
cohen
et
al
term
specif
deriv
word
speci
describ
characterist
speci
van
regenmortel
centuri
biolog
speci
consid
separ
clearcut
discontinu
nineteenth
centuri
bacteriologist
believ
antisera
rais
differ
speci
bacteria
complet
specif
allow
differ
speci
identifi
serolog
absolut
certainti
mazumdar
view
later
question
landstein
show
serolog
crossreact
differ
cell
type
caus
antibodi
react
differ
degre
wide
rang
cell
demonstr
onetoon
relationship
antigen
antibodi
antigen
could
elicit
wide
spectrum
antibodi
capabl
crossreact
mani
antigen
led
antigenantibodi
interact
regard
much
less
specif
previous
thought
nowaday
explain
widespread
occurr
crossreact
differ
epitop
paratop
work
landstein
led
talmag
suggest
immunolog
specif
result
uniqu
antibodi
molecul
recogn
distinguish
antigen
aros
combinatori
effect
sever
differ
antibodi
recogn
separ
epitop
antigen
accord
interpret
specif
antigen
recognit
elimin
process
alway
initi
sever
bind
event
involv
differ
antibodi
specif
defin
exact
complementari
relationship
agent
someth
act
medawar
medawar
definit
appli
stereochem
complementar
observ
antigen
antibodi
enzym
substrat
receptor
ligand
case
antibodi
recognit
complementari
antigen
mediat
bind
site
ig
molecul
consist
hypervari
residu
distribut
six
cdr
variabl
domain
heavi
light
ig
chain
immunoglobulin
bind
site
accommod
mani
overlap
nonoverlap
bind
subsit
residu
correspond
paratop
abl
bind
differ
antigen
ig
molecul
may
instanc
possess
two
independ
bind
site
allow
bind
simultan
phosphorylcholin
adgalactopyranosid
bhattacharje
glaudeman
common
situat
differ
paratop
subsit
partli
overlap
case
bind
one
epitop
would
prevent
second
relat
unrel
epitop
accommod
nearbi
locat
ig
bind
site
antibodi
molecul
therefor
polyspecif
sinc
alway
harbor
numer
subsit
correspond
paratop
specif
differ
epitop
flexibl
cdr
loop
also
contribut
abil
ig
adapt
varieti
epitop
ramsland
et
al
jame
et
al
jimenez
et
al
import
distinguish
actual
paratop
virtual
function
site
ig
molecul
consist
residu
six
cdr
howev
form
bind
site
particular
epitop
mani
term
crossreact
molecular
mimicri
plastic
promiscu
degeneraci
polyspecif
use
describ
find
cell
receptor
tcr
b
cell
receptor
bcr
recogn
mani
differ
ligand
cohn
sperl
et
al
parn
term
polyspecif
particularli
fit
captur
two
essenti
featur
immun
receptor
ie
abil
recogn
multipl
peptidemhc
major
histocompat
complex
ligand
b
cell
epitop
well
capac
distinguish
close
relat
ligand
present
small
structur
differ
wucherpfennig
et
al
term
crossreact
impli
particular
mechan
respons
recognit
suggest
primari
ligand
tcr
bcr
bind
ligand
case
crossreact
realiti
singl
intrins
real
epitop
immun
receptor
divers
group
potenti
ligand
wucherpfennig
et
al
crossreact
also
said
occur
immun
respons
result
secret
antibodi
direct
one
antigen
abl
interact
antigen
stimul
origin
reaction
parn
crossreact
refer
lack
specif
degeneraci
abil
element
structur
differ
perform
activ
function
degeneraci
may
yield
differ
function
depend
context
express
edelman
galli
genet
code
instanc
degener
mani
triplet
codon
encod
amino
acid
residu
result
enorm
number
structur
distinct
mrna
speci
could
translat
gener
amino
acid
sequenc
particular
protein
degeneraci
increas
one
includ
variat
polynucleotid
sequenc
result
mutat
function
equival
gene
product
edelman
galli
immunolog
degeneraci
refer
abil
structur
differ
antibodi
perform
recognit
function
also
abil
singl
antibodi
perform
multipl
function
like
bind
differ
antigen
degeneraci
properti
system
whole
singl
compon
parn
degeneraci
cell
recognit
refer
fact
peptidebind
motif
polyspecif
mhc
class
molecul
singl
tcr
activ
larg
number
differ
peptid
possess
limit
sequenc
similar
degeneraci
immunoglobulin
made
anim
ensur
anim
abil
make
antibodi
recogn
essenti
molecular
motif
immun
system
may
encount
immunolog
receptor
could
recogn
singl
complementari
ligand
immun
system
would
need
one
receptor
everi
possibl
epitop
would
requir
order
magnitud
receptor
cell
immun
system
polyspecif
complet
immun
repertoir
achiev
much
restrict
number
receptor
wucherpfennig
et
al
degeneraci
also
prerequisit
allow
organ
adapt
evolutionari
time
sinc
natur
select
oper
among
popul
dissimilar
organ
edelman
galli
descript
protein
bind
site
fuzzi
recognit
site
introduc
moodi
et
al
account
find
proteinligand
complementar
achiev
singl
arrang
amino
acid
larg
number
altern
arrang
epitop
also
call
fuzzi
recognit
site
clearcut
minimum
differ
bind
affin
atom
posit
antigenantibodi
interfac
serv
absolut
yardstick
decid
two
epitop
van
regenmortel
use
fuzzi
descriptor
realiti
use
handl
concept
entiti
possess
clearcut
boundari
mcneill
freiberg
wherea
classic
aristotelian
logic
analys
concept
class
term
mutual
exclus
dichotomi
type
glass
full
full
statement
true
true
fuzzi
logic
method
handl
continuum
innumer
step
mcneill
freiberg
van
regenmortel
sadeghzadeh
linguist
descriptor
often
assum
refer
entiti
possess
sharp
boundari
satisfi
propens
human
mind
want
make
clearcut
distinct
continu
natur
spectrum
electromagnet
wave
prevent
us
distinguish
differ
color
continu
geolog
rock
format
stop
us
give
differ
name
individu
mountain
peak
similar
way
continu
natur
biolog
variat
protein
evolut
prevent
us
distinguish
give
separ
name
individu
biolog
speci
antigen
bind
site
antibodi
van
regenmortel
even
classic
tenet
immunolog
theori
posit
need
immun
system
discrimin
self
nonself
cohn
interpret
term
fuzzi
recognit
site
leng
bentwich
complex
system
efroni
cohen
use
believ
cell
thymu
either
clearli
respons
unrespons
self
foreign
antigen
evid
mani
selfreact
cell
escap
clonal
select
result
low
affin
interact
selfpeptid
eventu
becom
part
gener
cell
repertoir
sandberg
et
al
occurr
antibodi
abl
react
foreign
antigen
result
select
forc
oper
immun
depend
reactant
concentr
probabl
receptor
bind
lymphocyt
stimul
occur
certain
trigger
threshold
foot
eisen
batista
neuberg
ig
molecul
found
bind
antigen
becom
possibl
solv
structur
antigenantibodi
complex
identifi
paratop
epitop
region
epitop
paratop
actual
relat
entiti
defin
mutual
complementar
depend
acquir
recogniz
ident
epitop
thu
intrins
structur
featur
protein
could
identifi
absenc
particular
interact
paratop
van
regenmortel
relat
depend
mean
soon
epitop
slightli
alter
bind
antibodi
affect
paratop
also
longer
result
analyz
antigen
protein
amount
analyz
size
immunolog
repertoir
host
immun
protein
number
epitop
identifi
protein
therefor
equal
number
differ
mab
rais
use
criterion
insulin
molecul
shown
possess
epitop
schroer
et
al
blyss
molecul
thousand
edward
et
al
analysi
differ
viewpoint
advoc
cohn
defin
paratop
clan
famili
paratop
distinguish
one
function
capabl
recogn
given
singl
epitop
cohn
defin
mimotop
array
set
epitop
distinguish
one
abl
interact
function
given
singl
paratop
accept
entir
access
surfac
protein
harbour
larg
number
overlap
epitop
detect
mab
bind
region
avail
benjamin
et
al
berzofski
mean
residu
surfac
protein
alway
part
differ
overlap
epitop
even
major
residu
recogn
two
differ
mab
chemic
bond
pattern
epitop
paratop
may
differ
involv
total
unrel
cdr
sequenc
van
regenmortel
small
number
mab
avail
studi
antigen
protein
investig
tend
give
undu
import
spuriou
boundari
assum
demarc
discret
antigen
region
disregard
fact
protein
surfac
antigen
continuum
lead
analyt
bia
emphas
immun
respons
elicit
singl
epitop
rather
foster
examin
benefici
neutral
synergi
often
result
combin
interact
sever
independ
epitop
paratop
tilley
et
al
laal
et
al
zwick
et
al
restrict
one
attent
singl
epitop
also
negat
insight
talmag
specif
interact
result
combin
effect
sever
independ
recognit
event
although
imposs
draw
distinct
boundari
overlap
epitop
customari
refer
exist
separ
antigen
site
protein
one
compris
mani
overlap
nonoverlap
epitop
antigen
site
identifi
protein
surfac
basi
recogniz
spatial
locat
well
certain
structur
function
properti
sever
antigen
site
env
spike
extens
studi
instanc
bind
site
region
allow
viru
attach
primari
receptor
surfac
target
cell
li
et
al
berzofski
zhou
et
al
antigen
site
zollapazn
javaherian
et
al
hioe
et
al
membran
proxim
extern
region
mper
montero
et
al
muster
et
al
zwick
must
stress
hn
antigen
site
consist
sever
overlap
epitop
may
give
rise
neutral
synergi
phenomena
may
overlook
one
epitop
recogn
mab
use
studi
antigen
site
antibodi
heterospecif
abil
antibodi
bind
strongli
differ
antigen
one
use
rais
antibodi
frequent
observ
antibodi
test
seri
analog
mutant
immunogen
loor
al
moudal
et
al
underwood
harper
et
al
heterospecif
due
fact
clonal
select
b
cell
subsequ
lead
antibodi
secret
plasma
cell
trigger
immunogen
endow
moder
affin
b
cell
receptor
antibodi
low
moder
affin
obtain
may
react
better
heterolog
epitop
endow
superior
degre
complementar
paratop
van
regenmortel
case
antibodi
may
low
affin
immunogen
react
bind
mutat
antigen
present
substitut
facilit
heterospecif
bind
techniqu
intragel
crossabsorpt
antisera
particularli
suitabl
detect
phenomenon
van
regenmortel
wellknown
follow
immun
antigen
antisera
obtain
contain
level
total
immunoglobulin
far
exceed
level
antibodi
abl
react
immunoassay
administ
antigen
eisen
like
explan
differ
b
cell
respons
degener
trigger
secret
ig
function
detect
antibodi
homolog
antigen
also
heterospecif
antibodi
affin
immunogen
threshold
requir
bind
although
may
abl
bind
relat
antigen
specif
antibodi
invers
relat
abil
crossreact
varieti
antigen
berzofski
schechter
part
confus
surround
concept
specif
aris
distinct
made
singl
epitop
multiepitop
antigen
investig
wish
differenti
two
antigen
relat
protein
use
panel
mab
antibodi
recogn
epitop
molecul
would
call
nonspecif
wherea
antibodi
recogn
epitop
present
one
would
consid
specif
van
regenmortel
sinc
antibodi
would
thu
call
specif
non
specif
depend
investig
tri
achiev
prefer
refer
discrimin
potenti
antibodi
rais
multiepitop
antigen
antibodi
cours
specif
multiepitop
protein
best
limit
specif
individu
epitop
antibodi
alway
abl
crossreact
mani
relat
epitop
also
demonstr
abil
larg
number
peptid
analog
present
amino
acid
replac
residu
posit
react
antibodi
getzoff
et
al
geysen
et
al
robert
et
al
often
believ
antibodi
specif
correl
high
affin
expect
highli
specif
antibodi
possess
better
stereochem
complementar
antigen
antibodi
lower
affin
howev
necessari
link
affin
specif
sinc
antibodi
lower
affin
may
discrimin
better
two
antigen
antibodi
higher
affin
reason
low
affin
antibodi
tend
detect
fewer
crossreact
antibodi
high
affin
sinc
crossreact
usual
weaker
homolog
reaction
quickli
drop
level
detect
van
regenmortel
must
also
emphas
way
epitop
paratop
defin
mutual
relationship
affin
antibodi
defin
respect
binari
relationship
singl
antigen
contrast
specif
antibodi
ternari
relat
properti
meaning
respect
complex
set
relat
one
antibodi
least
two
antigen
reason
specif
aris
abil
antibodi
react
differ
two
antigen
thu
discrimin
failur
revers
vaccinolog
develop
vaccin
partli
due
unwarr
expect
structur
delin
discontinu
epitop
bound
neutral
mab
allow
epitop
use
success
vaccin
immunogen
discuss
discontinu
epitop
correspond
set
noncontigu
residu
isol
separ
entiti
show
possess
bind
activ
outsid
protein
context
mani
unsuccess
attempt
made
reconstitut
exact
structur
discontinu
epitop
chemic
synthesi
van
regenmortel
refer
therein
timmerman
et
al
seem
possibl
reproduc
exact
immunolog
activ
absenc
scaffold
contribut
peptid
chain
result
immunogen
capac
discontinu
epitop
evalu
use
nativ
protein
embed
immunogen
procedur
alway
stimul
heterogen
immun
respons
numer
epitop
protein
instanc
antibodi
rais
surfac
possess
except
neutral
capac
mab
pantophlet
et
al
multiepitop
protein
use
immunogen
variou
epitop
select
bind
b
cell
receptor
present
immun
host
possess
suffici
affin
howev
epitop
preferenti
bind
rare
receptor
addit
recogn
epitop
respons
subsequ
secret
plasmocyt
antibodi
neutral
viral
infect
select
b
cell
receptor
immun
blind
presenc
neutral
antivir
activ
antibodi
secret
sinc
biolog
function
becom
effect
subsequ
infect
host
furthermor
even
singl
discontinu
epitop
could
somehow
use
immunogen
probabl
still
extrem
low
select
b
cell
receptor
would
present
immun
host
exactli
match
variabl
immunoglobulin
gene
cdr
sequenc
mab
use
identifi
discontinu
epitop
unfortun
know
elicit
neutral
rather
nonneutr
antibodi
sinc
clear
featur
immunogen
immun
host
respons
crossprotect
immunogen
activ
requir
vaccin
candid
zwick
burton
parren
burton
van
regenmortel
read
dimmock
difficulti
encount
one
attempt
design
vaccin
immunogen
basi
known
structur
neutral
antibodi
recogn
discontinu
epitop
clearli
demonstr
case
antibodi
mab
obtain
phagedisplay
fab
librari
deriv
patient
burton
et
al
recogn
conserv
discontinu
epitop
overlap
neutral
wide
rang
primari
tcla
isol
inhibit
bind
receptor
antibodi
long
cdr
region
featur
present
mani
human
mab
allow
penetr
hydrophob
caviti
surfac
use
dock
model
onto
sever
contact
residu
epitop
identifi
contribut
bind
activ
evalu
alanin
mutagenesi
saphir
et
al
structur
use
dock
one
avail
time
correspond
monomer
core
complex
fab
kwong
et
al
may
therefor
correspond
conform
trimer
seen
antibodi
immun
system
known
bind
undergo
larg
conform
chang
allow
viru
bind
one
chemokin
coreceptor
labrijn
et
al
decker
et
al
attempt
identifi
vaccin
immunogen
capabl
elicit
neutral
antibodi
peptid
librari
display
filament
phage
use
select
peptid
bind
zwick
et
al
peptid
label
sequenc
found
bind
consider
affin
present
disulfidebridg
homodim
involv
two
residu
residu
peptid
present
sever
select
mimotop
peptid
consid
respons
bind
activ
zwick
et
al
peptid
show
signific
homolog
dloop
region
residu
appear
exact
conform
mimic
dloop
region
immunogen
test
mice
rabbit
antibodi
obtain
crossreact
indic
effect
candid
vaccin
immunogen
anoth
studi
addit
mimotop
react
obtain
possess
consensu
sequenc
mvhsd
h
repres
aromat
amino
acid
found
peptid
dorgham
et
al
second
third
gener
librari
construct
gave
rise
improv
consensu
sequenc
gsllmvwsdelh
react
even
strongli
phagedisplay
peptid
contain
sequenc
compet
bind
therefor
consid
mimic
epitop
recogn
contrast
found
peptid
immun
activ
phagedisplay
mimotop
abl
elicit
envspecif
antibodi
although
immun
mimotop
conjug
carrier
protein
crossreact
immun
sera
immun
mice
howev
neutral
laboratoryadapt
strain
vitro
show
improv
mimotop
also
ineffect
vaccin
immunogen
dorgham
et
al
conclus
immun
peptid
mimic
discontinu
epitop
feasibl
approach
develop
epitopetarget
vaccin
corrobor
recent
studi
mimotop
mimick
discontinu
epitop
three
wellcharacter
protein
irv
et
al
inabl
mimotop
react
antibodi
elicit
antibodi
due
fact
linear
peptid
reproduc
complex
structur
featur
discontinu
epitop
recogn
mab
presum
induc
format
clearli
demonstr
crystal
structur
complex
fab
peptid
determin
saphir
et
al
three
critic
bind
residu
peptid
residu
found
form
sidechain
contact
paratop
residu
import
bind
activ
help
stabil
peptid
structur
peptid
abl
bind
mimic
dloop
react
differ
paratop
subsit
one
recogn
complex
discontinu
epitop
determin
dock
mutagenesi
studi
zwick
et
al
pantophlet
et
al
sinc
peptid
mimick
best
small
portion
discontinu
epitop
recogn
surpris
peptid
unabl
elicit
antibodi
crossreact
saphir
et
al
attempt
understand
mab
possess
potent
neutral
properti
wherea
major
anti
cdrb
mab
residu
mutat
alanin
determin
whether
substitut
affect
abil
bind
neutral
nonneutr
mab
pantophlet
et
al
mani
substitut
found
affect
bind
neutral
nonneutr
mab
way
indic
high
degre
overlap
epitop
recogn
antibodi
mutat
enhanc
mab
bind
effect
never
observ
bind
suggest
viru
evolv
toward
optim
interact
although
individu
differ
effect
substitut
bind
differ
mab
clear
pictur
emerg
explain
possess
uniqu
neutral
capac
sinc
certain
residu
loop
abl
affect
bind
suggest
nonneutr
mab
might
interact
surfac
use
differ
orient
one
use
pantophlet
et
al
known
mab
bind
monomer
similarli
independ
neutral
capac
wherea
abl
bind
trimer
function
presum
neotop
present
oligom
may
reason
nativ
trimer
abl
elicit
effect
neutral
antibodi
respons
parren
burton
sattentau
moor
attempt
find
immunogen
abl
elicit
antibodi
base
premis
immunogen
must
reproduc
exactli
structur
epitop
recogn
assum
antigen
activ
epitop
alway
accompani
relat
immunogen
activ
assumpt
impli
antigen
chemic
properti
aris
molecular
recognit
process
involv
complementari
antibodi
equival
immunogen
biolog
properti
lead
antibodi
secret
occur
context
immun
host
van
regenmortel
immunogen
depend
intrins
properti
immunogen
also
extrins
factor
control
constitu
properti
host
immun
system
host
ig
gene
repertoir
appropri
bcr
cytokin
etc
berek
harwood
batista
extrins
factor
contribut
occurr
neutral
antibodi
initi
use
identifi
put
vaccin
epitop
expect
present
ident
form
host
vaccin
antigen
anoth
reason
make
imposs
extrapol
antigen
immunogen
structur
structur
epitop
determin
crystallograph
complex
also
influenc
process
induc
fit
conform
select
mutual
adapt
two
bind
partner
rini
et
al
wilson
stanfield
berger
et
al
bosshard
goh
et
al
result
particular
antigen
structur
reveal
antigenantibodi
complex
necessarili
correspond
immunogen
structur
recogn
b
cell
receptor
immun
process
present
vaccin
immunogen
van
regenmortel
test
immunoassay
peptid
may
bind
antiprotein
neutral
mab
induc
fit
mechan
driven
preexist
structur
mab
howev
induc
fit
occur
peptid
use
immunogen
recogn
b
cell
receptor
special
affin
cognat
intact
protein
assumpt
immunogen
potenti
deduc
antigen
structur
led
sever
group
modifi
molecul
order
improv
vaccin
potenti
instanc
recombin
gener
longer
abl
bind
nonneutr
anti
mab
retain
capac
bind
approach
call
immunofocus
pantophlet
burton
hope
reengin
would
acquir
immunogen
capac
elicit
neutral
antibodi
somehow
mirror
alter
antigen
reactiv
pantophlet
et
al
expect
subsequ
report
indic
attempt
induc
immunogen
function
mirror
antigen
properti
engin
construct
success
recent
stabil
antigen
better
abl
bind
neutral
antibodi
develop
ration
design
wu
et
al
env
reengin
delet
loop
full
molecul
introduc
crosslink
differ
region
core
protein
one
reengin
stabil
surfac
react
strongli
mab
four
nonneutr
mab
use
select
mab
memori
b
cell
deriv
clade
binfect
donor
small
number
memori
b
cell
obtain
million
peripher
blood
mononuclear
cell
donor
one
select
mab
neutral
nearli
hiv
isol
multipl
clade
much
broader
neutral
capac
wu
et
al
author
suggest
result
provid
import
insight
futur
vaccin
design
although
present
evid
ration
design
antigen
also
superior
immunogen
abl
induc
polyclon
antibodi
human
although
mani
linear
peptid
sequenc
protein
crossreact
antibodi
rais
protein
mostli
unabl
elicit
antibodi
crossreact
nativ
protein
lack
crossreact
immunogen
peptid
van
regenmortel
explain
follow
antiprotein
antibodi
test
abil
react
peptid
immunoassay
may
select
one
mani
avail
peptid
conform
may
bring
induc
fit
result
case
detect
crossreact
contrast
peptid
confront
varieti
b
cell
receptor
immun
differ
conform
peptid
may
recogn
separ
receptor
lead
subsequ
appear
varieti
antipeptid
antibodi
howev
reason
peptid
would
bind
preferenti
rare
receptor
addit
also
crossreact
complex
epitop
present
nativ
protein
sinc
peptid
correspond
continu
epitop
nearli
alway
poor
mimic
protein
discontinu
epitop
unlik
signific
proport
elicit
antipeptid
antibodi
would
react
cognat
protein
antibodi
recogn
viral
protein
cours
possess
neutral
activ
sometim
possibl
improv
crossreact
immunogen
peptid
increas
conform
similar
peptid
intact
protein
instanc
cycliz
peptid
approach
rare
succe
produc
immunogen
abl
elicit
neutral
antibodi
van
regenmortel
refer
therein
joyc
et
al
ho
et
al
mention
earlier
case
discontinu
epitop
linear
peptid
correspond
continu
epitop
use
immunogen
preferenti
select
bind
rare
b
cell
receptor
addit
crossreact
nativ
protein
also
trigger
b
cell
differenti
process
give
rise
antibodi
endow
function
protect
activ
although
mimotop
sever
continu
epitop
differ
virus
includ
found
abl
elicit
antibodi
crossreact
viru
possess
neutral
activ
yu
et
al
steward
et
al
scala
et
al
success
protect
peptidebas
antivir
vaccin
develop
market
human
use
han
et
al
two
long
continu
epitop
locat
conserv
region
mper
regard
promis
vaccin
candid
zwick
mani
group
attempt
turn
effect
vaccin
immunogen
montero
et
al
seem
highli
unlik
howev
short
linear
peptid
part
larger
complex
discontinu
epitop
elicit
potent
neutral
mab
abl
induc
effect
protect
immun
respons
van
regenmortel
termin
region
protein
frequent
harbour
continu
epitop
tend
surfaceori
hydrophil
mobil
intern
region
thornton
sibanda
westhof
et
al
tainer
et
al
pellequ
et
al
major
purpos
epitop
predict
replac
intact
antigen
molecul
linear
synthet
peptid
use
diagnost
reagent
detect
viral
antibodi
leinikki
et
al
immunogen
rais
antipeptid
antibodi
abl
crossreact
parent
protein
walter
muller
effect
strategi
case
select
long
synthet
peptid
correspond
n
ctermin
region
protein
sinc
highest
probabl
crossreact
antigen
protein
method
predict
continu
epitop
protein
like
effect
vaccin
immunogen
notori
unsuccess
ponomarenko
van
regenmortel
greenbaum
et
al
blyth
flower
caioli
limit
success
obtain
certain
termin
peptid
use
vaccin
immunogen
vaccin
ntermin
peptid
protein
canin
parvoviru
instanc
abl
protect
dog
viru
infect
langeveld
et
al
anoth
exampl
ctermin
region
protein
residu
footandmouth
diseas
viru
abl
elicit
high
level
neutral
antibodi
bittl
et
al
residu
one
subunit
locat
next
immunodomin
disord
loop
residu
adjac
subunit
rowland
et
al
region
contribut
singl
discontinu
neotop
parri
et
al
abil
termin
region
protein
induc
antibodi
crossreact
nativ
protein
partli
due
fact
region
possess
intrins
disord
make
similar
unstructur
peptid
uverski
et
al
although
disord
region
protein
may
recogn
preferenti
antipeptid
antibodi
major
viral
epitop
capabl
induc
neutral
antibodi
respons
actual
complex
discontinu
topograph
site
rather
termin
linear
peptid
loop
turn
protein
often
immunodomin
antigen
region
loop
mani
year
consid
princip
neutral
domain
viru
javaherian
et
al
spear
et
al
although
design
third
variabl
domain
loop
mani
conserv
featur
constant
size
residu
conserv
type
ii
turn
tip
disulfid
bond
base
jiang
et
al
semiconserv
natur
loop
allow
play
import
role
recognit
viral
coreceptor
sequenc
variabl
led
investig
question
valu
target
vaccineinduc
antibodi
anoth
reason
led
investig
doubt
valu
loop
vaccin
candid
look
presenc
anti
antibodi
human
antisera
absorb
sera
linear
peptid
van
cott
et
al
sinc
absorpt
step
remov
antibodi
neutral
primari
isol
conclud
neutral
antibodi
direct
loop
fact
human
sera
neutral
tcla
isol
primari
isol
sever
clade
contain
antibodi
recogn
cyclic
conform
present
viru
disulfidebond
loop
absent
linear
peptid
zollapazn
gorni
et
al
hioe
et
al
kayman
et
al
gorni
et
al
loop
flexibl
abl
adopt
differ
conform
bind
differ
mab
stanfield
et
al
found
altern
conform
induc
peptid
depend
whether
bind
mab
neutral
virus
mab
neutral
virus
rosen
et
al
show
epitop
conform
observ
mabepitop
complex
result
induc
fit
process
therefor
reliabl
guid
decid
immunogen
conform
use
elicit
certain
type
neutral
antibodi
yet
clear
whether
intrins
flexibl
loop
constrain
particular
conform
increas
potenti
valu
vaccin
candid
mester
et
al
case
immunodomin
gh
loop
residu
protein
footandmouth
diseas
viru
stabil
alld
retro
loop
synthes
damino
acid
found
induc
higher
level
neutral
antibodi
correspond
lpeptid
briand
et
al
carver
et
al
nargi
et
al
sever
reason
strategi
use
success
past
develop
effect
vaccin
mani
viral
diseas
applic
hilleman
kuster
almond
virgin
walker
sinc
natur
immun
respons
infect
individu
clear
infect
natur
immunolog
mechan
vaccin
could
imit
vaccin
would
thu
surpass
normal
immun
respons
induc
infect
would
instanc
gener
far
stronger
respons
conserv
epitop
occur
infect
integr
host
genom
establish
latent
pool
infect
cell
conceal
viru
immun
recognit
viru
progress
destroy
immun
system
isol
exhibit
enorm
antigen
variabl
aris
errorpron
viral
revers
transcript
produc
much
sequenc
divers
viral
subtyp
divers
singl
infect
individu
although
increas
number
broadli
neutral
mab
recent
isol
infect
human
donor
stamatato
et
al
scheid
et
al
walker
et
al
corti
et
al
mascola
montefiori
antibodi
rare
induc
experiment
immun
seem
infect
immun
respons
mostli
direct
highli
variabl
access
env
region
loop
rather
function
import
less
access
conserv
domain
receptor
coreceptor
bind
site
propens
immun
system
respond
immunodomin
strainspecif
highli
variabl
antigen
site
instead
subdomin
conserv
epitop
abl
principl
elicit
broadli
protect
immun
call
decept
imprint
allow
viru
escap
immun
pressur
nara
garriti
attempt
overcom
decept
imprint
redirect
immun
respons
less
strainspecif
epitop
made
use
strategi
call
immun
refocus
introduc
sever
new
glycosyl
site
loop
possibl
instanc
obtain
immunogen
induc
broader
neutral
respons
effect
heterolog
strain
tobin
et
al
report
immun
result
howev
difficult
interpret
linear
instead
cycliz
loop
peptid
use
inhibit
experi
aim
determin
specif
induc
antibodi
attempt
also
made
redirect
immun
respons
conserv
neutral
epitop
delet
variabl
loop
env
result
satisfactori
lu
et
al
kim
et
al
approach
overcom
problem
extens
antigen
variabl
includ
use
immunogen
either
artifici
consensu
sequenc
base
common
amino
acid
posit
align
gaschen
et
al
mcburney
ross
altern
combinatori
converg
peptid
librari
consist
thousand
peptid
known
mixotop
recogn
singl
entiti
immun
receptor
grasmass
et
al
strategi
deal
exist
mani
antigen
variant
mean
polyval
vaccin
cocktail
also
propos
korber
gnanakaran
recent
result
shown
loop
may
fact
abl
induc
neutral
respons
mani
differ
clade
indic
polyclon
respons
may
much
greater
neutral
breadth
display
singl
mab
even
cocktail
mab
hioe
et
al
jiang
et
al
pantophlet
et
al
pervad
theme
current
vaccin
research
belief
ration
design
offer
best
prospect
much
need
develop
effect
vaccin
hivaid
tuberculosi
malaria
bramwel
perri
argenio
wilson
mcelrath
hayn
sett
rappuoli
case
viewpoint
led
claim
ration
design
repres
approach
elev
vaccin
research
empir
exercis
scientif
disciplin
karlssonhedestam
et
al
argu
view
denigr
timehonour
empir
trialanderror
approach
gave
us
present
day
effect
vaccin
highli
mislead
could
even
possibl
jeopard
futur
effort
develop
vaccin
van
regenmortel
alway
clear
scientist
mean
refer
ration
design
may
help
briefli
analyz
term
label
ration
tend
use
describ
approach
reli
probabl
outcom
intervent
predict
avail
scientif
knowledg
term
ration
also
use
describ
common
sens
decis
focus
known
antigen
region
viral
protein
primari
target
vaccin
obeid
et
al
sinc
scientif
work
base
reason
logic
current
accept
scientif
theori
make
littl
sens
oppos
ration
empir
approach
sinc
scientif
knowledg
deriv
empir
observ
made
cours
experi
necessarili
plan
analyz
ration
manner
therefor
mislead
impli
trialanderror
experiment
ration
sinc
novel
find
discoveri
aris
unpredict
outcom
control
experi
rather
pure
ration
deduct
think
van
regenmortel
term
design
defin
deliber
intellig
conceiv
artifici
object
process
design
task
pose
solv
invers
problem
name
imagin
basi
exist
knowledg
would
bring
desir
outcom
bung
plausibl
solut
test
trial
error
preset
goal
attain
van
regenmortel
sinc
scientist
need
secur
fund
research
tempt
suggest
current
understand
complex
immun
system
suffici
allow
design
immunogen
predict
type
antibodi
elicit
ration
design
terminolog
impli
causal
relationship
structur
antibodi
function
give
rise
assert
structur
determin
function
although
true
biolog
activ
alway
depend
underli
structur
structur
possess
causal
efficaci
bring
certain
activ
causal
relat
relat
success
event
two
materi
object
structur
event
van
regenmortel
uniqu
causal
relat
structur
antibodi
neutral
capac
sinc
occurr
neutral
influenc
larg
number
immunolog
pathophysiolog
factor
aris
complex
interact
antibodi
pathogen
host
isol
potent
neutral
mab
wu
et
al
elucid
structur
zhou
et
al
well
isol
mani
addit
broadli
neutral
antibodi
serum
infect
donor
walker
et
al
corti
et
al
mascola
montefiori
binley
et
al
gray
et
al
interpret
provid
valuabl
molecular
inform
facilit
ration
vaccin
design
burton
weiss
search
addit
broadli
neutral
mab
stimul
find
possibl
provid
steril
protect
nonhuman
primat
administ
neutral
mab
prior
viral
challeng
howev
type
success
immunotherapi
use
neutral
antibodi
deriv
infect
individu
way
tell
us
antibodi
induc
vaccin
precis
lack
knowledg
regard
immunogen
abl
induc
antibodi
certain
infect
individu
prevent
us
develop
vaccin
design
furthermor
polyspecif
antibodi
molecul
degeneraci
immun
system
impli
futil
search
singl
intrins
epitop
neutral
mab
put
uniqu
immunogen
structur
capabl
induc
protect
antibodi
claim
virgin
walker
failur
develop
vaccin
due
fact
understand
type
immun
respons
need
protect
cours
surmis
effect
bcell
respons
need
littl
help
sinc
know
elicit
requir
respons
immun
one
could
also
argu
studi
mechan
prevent
therapeut
vaccin
becom
possibl
effect
vaccin
protocol
discov
empir
figur
list
mani
question
need
answer
want
abl
ration
design
vaccin
van
regenmortel
virgin
walker
ebensen
guzman
suggest
ration
design
may
best
strategi
follow
tobin
et
al
sinc
possibl
instanc
predict
combin
sever
substitut
protein
may
lead
new
desir
properti
manifest
protein
present
one
substitut
led
conclus
improv
protein
function
like
obtain
success
round
random
mutat
recombin
select
ration
design
van
regenmortel
refer
therein
cours
possibl
ration
design
antigen
fit
singl
mab
wu
et
al
villen
et
al
improv
molecular
design
paratop
bind
efficaci
mab
intend
passiv
immunotherapi
possibl
ration
design
immunogen
molecul
elicit
protect
polyclon
antibodi
respons
predetermin
efficaci
exist
among
infect
individu
longterm
nonprogressor
ltnp
elit
control
ec
given
rise
hope
elucid
mechan
respons
occurr
may
help
vaccin
design
poropatich
sullivan
ltnp
make
seroposit
individu
okulicz
et
al
maintain
low
plasma
level
hivrna
elev
cell
level
wherea
even
rarer
ec
individu
undetect
level
viral
rna
combin
viral
genet
immunolog
factor
implic
abil
slow
progressor
control
infect
princip
viral
factor
believ
slow
diseas
progress
strain
attenu
aris
mutat
viral
accessori
gene
caus
reduct
viru
infect
replic
poropatich
sullivan
control
diseas
progress
individu
result
infect
attenu
poorli
replic
virus
clear
could
made
use
vaccin
develop
appli
host
genet
immunolog
factor
promot
control
infect
chemokin
receptor
polymorph
presenc
certain
protect
hla
class
allel
ltnp
ec
individu
although
slow
progressor
shown
abl
induc
broadli
neutral
antibodi
multipl
strain
villen
et
al
simek
et
al
relev
antienv
immun
respons
vaccin
design
also
obviou
sinc
know
immunogen
abl
induc
respons
inde
gener
recogn
major
bottleneck
design
vaccin
lie
ignor
immunogen
capabl
induc
broadli
neutral
immun
respons
stamatato
et
al
mascola
montefiori
mcelrath
hayn
discuss
review
success
design
strategi
requir
know
immunogen
immunolog
mechan
like
lead
appear
protect
immun
follow
vaccin
unfortun
even
vaccin
induc
high
level
neutral
antibodi
necessarili
protect
viru
infect
mascola
mani
investig
recent
stress
need
embark
larg
scale
research
program
basic
preclin
immunolog
believ
give
us
understand
requir
design
vaccin
virgin
walker
mcelrath
hayn
although
nobodi
would
quarrel
need
basic
research
immunolog
track
record
vaccinolog
show
effect
vaccin
past
alway
discov
trialanderror
immun
trial
rather
ration
design
base
avail
structur
immunolog
knowledg
widespread
current
expect
discoveri
biomedicin
vaccinolog
like
result
structurebas
molecular
studi
omic
type
investig
sett
rappuoli
system
biolog
approach
pulendran
et
al
rather
empir
trial
may
well
turn
counterproduct
inhibit
investig
undertak
exploratori
trialanderror
experi
empir
immunogen
trial
base
less
perfect
understand
complex
immun
respons
natur
dynam
transitori
epitop
may
still
key
discov
promis
vaccin
candid
although
epitop
map
neutral
mab
structur
analys
may
help
investig
identifi
region
viral
surfac
target
vaccin
must
emphas
antigen
map
lead
discoveri
vaccin
immunogen
reveal
follow
experiment
immunogen
trial
identifi
mani
crossreact
epitop
neutral
mab
recogn
entir
differ
task
discov
empir
vaccin
immunogen
abl
induc
protect
immun
respons
effect
immunogen
identifi
empir
may
still
take
mani
year
basic
research
establish
mechan
action
case
present
day
success
vaccin
even
conceiv
may
never
fulli
understand
empir
discov
vaccin
actual
effect
salutari
remind
discov
effect
vaccin
empir
higher
prioriti
elucid
mode
action
ideal
vaccin
basic
immunolog
research
therefor
stand
way
ration
immunogen
trial
restrict
financi
resourc
must
made
avail
implement
creativ
imagin
think
requir
choos
credibl
candid
vaccin
invent
plausibl
hypothes
help
select
judici
vaccin
regimen
dosag
adjuv
deliveri
rout
effect
cell
help
instead
misrepres
experiment
hypothesi
test
case
ration
design
would
seem
prefer
openli
acknowledg
empir
test
immunogen
initi
take
form
small
human
trial
still
offer
best
hope
discov
effect
vaccin
increas
doubt
develop
prevent
vaccin
abl
provid
prophylact
immun
stop
infect
occur
altogeth
realist
enterpris
inde
evid
possibl
induc
suffici
high
level
broadli
neutral
antibodi
mucos
surfac
achiev
aim
recent
year
much
research
direct
instead
develop
therapeut
vaccin
treat
peopl
alreadi
infect
shown
instanc
immun
conserv
hiv
regulatori
protein
tat
rev
nef
first
protein
express
hiv
infect
abl
stimul
immun
system
patient
receiv
antiretrovir
therapi
enabl
partial
control
viru
replic
caputo
et
al
therapeut
vaccin
current
investig
et
al
li
et
al
may
becom
possibl
assess
valu
rapidli
futur
use
socal
adapt
trial
design
aim
screen
poor
vaccin
extend
evalu
efficaci
one
corey
et
al
addit
sinc
mani
method
avail
chemic
inactiv
retain
conform
function
integr
gp
protein
van
regenmortel
refer
therein
may
justifi
reexamin
possibl
valu
kill
vaccin
provid
total
innocu
inactiv
genet
modifi
viru
establish
unexpect
promis
result
thailand
trial
initi
condemn
illconceiv
unjustifi
burton
et
al
mcneil
et
al
belsh
et
al
jefferi
harrington
turn
first
human
vaccin
trial
show
modest
protect
hiv
infect
rerksngarm
et
al
letvin
demonstr
empir
trial
alway
need
sinc
outcom
inher
unpredict
